EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib

Mio Tsuruoka, Masashi Ninomiya, Jun Inoue, Tomoaki Iwata, Akitoshi Sano, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Atsushi Masamune

Oncology · 2024

DOI: 10.1159/000540438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Mio Tsuruoka und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan, ytrsb237@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines, Phenylurea Compounds. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cell-free DNA (cfDNA) is expected to contribute to the decision for treatment and prediction of effects with minimally invasion. We investigated the correlation between gene mutations before and after lenvatinib (LEN) treatment and its effectiveness, in order to find advanced hepatocellular carcinoma (HCC) patients who would benefit greatly from the therapy.

Methods

We analyzed cfDNA before and 6–8 weeks after the start of treatment in 20 advanced HCC patients who started LEN. A next-generation sequencer was used for CTNNB1 and TP53. Concerning TERT promoter, −124C>T and −146C>T mutations are researched using digital PCR. In addition, we examined liver tumor biopsy tissues by the same method. Computerized tomography evaluation was performed at 6–8 weeks and 3–4 months to assess the efficacy.

Results

Frequencies of TERT promoter, CTNNB1, and TP53 mutations in pretreatment cfDNA were 45%, 65%, and 65%, but 53%, 41%, and 47% in HCC tissues, respectively. There were no clear correlations between these gene mutations and the disease-suppressing effect or progression-free survival. Overall, there were many cases showing a decrease in mutations after LEN treatment. Integrating the reduction of CTNNB1 and TP53 genetic mutations increased the potential for disease suppression.

Conclusion

This study suggests that analysis of cfDNA in advanced HCC patients may be useful for identifying LEN responders and determining therapeutic efficacy. Furthermore, it has potential for selecting responders for other molecular-targeted drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsQuinolinesPhenylurea CompoundsMutationTelomeraseCell-Free Nucleic Acidsbeta CateninHumansMaleFemaleMiddle AgedAgedTumor Suppressor Protein p53Antineoplastic AgentsPromoter Regions, GeneticAdultAged, 80 and overProgression-Free Survival

Stichwörter der Autor:innen

CTNNB1Cell-free DNAHepatocellular carcinomaLenvatinibLiver tumor biopsyNext-generation sequencerTP53Telomerase reverse transcriptase promoter

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsTelomeraseCell-Free Nucleic Acidsbeta CateninTERT protein, humanCTNNB1 protein, humanTumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan, ytrsb237@gmail.com.
  • Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Zitieren

APA

Tsuruoka, M., Ninomiya, M., Inoue, J., Iwata, T., Sano, A., Sato, K., Onuki, M., Sawahashi, S., & Masamune, A. (2024). Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib. Oncology. https://doi.org/10.1159/000540438

Vancouver

Tsuruoka M, Ninomiya M, Inoue J, Iwata T, Sano A, Sato K, et al. Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib. Oncology. 2024. doi:10.1159/000540438

BibTeX
@article{Tsuruoka2024,
  author = {Tsuruoka, Mio and Ninomiya, Masashi and Inoue, Jun and Iwata, Tomoaki and Sano, Akitoshi and Sato, Kosuke and Onuki, Masazumi and Sawahashi, Satoko and Masamune, Atsushi},
  title = {Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000540438}
}
Kostenlos starten →